Shots: 

• The company has reported the first patient dosing in P-l study assessing the safety- tolerability- and immunogenicity of HLX11 vs US-- EU- and China-sourced reference pertuzumab in healthy Chinese male
• The 1EPs of the study is to compare the PK b/w HLX11 and the three different sourced reference drugs head-to-head while the 2EPs is to evaluate the safety- tolerability- and immunogenicity of HLX11 and the reference drug- further describing the PK profile
• HLX11 can be potentially used for the treatment of HER2-positive mBC & eBC. Additionally- the study demonstrated that combining pertuzumab with trastuzumab and CT can decrease the risk of recurrence or death for HER2+ BC

­ Ref: Henlius | Image: Henlius